Current Allergy and Asthma Reports

, Volume 12, Issue 1, pp 18–24

Eosinophilic Disorders in Various Diseases

Basic and Applied Science (M Frieri, Section Editor)

Abstract

Peripheral and tissue eosinophilia are usually associated with a variety of inflammatory, malignant, and infectious conditions. As the presence of eosinophils in the tissues may cause significant cellular damage to vital organs such as the heart, tissue eosinophilia should be diagnosed and treated promptly. One operative way to evaluate eosinophilic disorders is to classify them into extrinsic and intrinsic. While extrinsic eosinophilic disorders are usually due to the production of eosinopoietic factors derived from T cells or tumor cells, the intrinsic types generally are the result of genetic mutations in the eosinophilic lineage. As we understand more the biology of eosinophils, only a few eosinophilic disorders remain idiopathic. The purpose of this article is to help the clinician classify in an operational manner most eosinophilic disorders, using the extrinsic and intrinsic model. This may facilitate not only a better understanding of the role of eosinophils in these disorders, but also help the systematic clinical work-up and potential treatment of affected patients.

Keywords

Eosinophils Eosinophilic disorders Interleukins Eotaxin T cells Inflammation Eosinopoietic Imatinib Eosinophilic esophagitis 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Ehrlich P, Beiträge zur Kenntnis der granulierenden Bindegewebszellen und der eosinophilen Leukocyten. Arch Anat Physiol 1879; 166–169.Google Scholar
  2. 2.
    Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol. 2006;24:147–74.PubMedCrossRefGoogle Scholar
  3. 3.
    Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood. 1992;79:3101–9.PubMedGoogle Scholar
  4. 4.
    Simon D, Simon HU. Eosinophilic disorders. J Allergy Clin Immunol. 2007;119:1291–300.PubMedCrossRefGoogle Scholar
  5. 5.
    Ellis AK, Keith PK. Nonallergic rhinitis with eosinophilia syndrome. Curr Allergy Asthma Res. 2006;6:215–20.CrossRefGoogle Scholar
  6. 6.
    Lecki MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet. 2000;356:2144–8.CrossRefGoogle Scholar
  7. 7.
    Apter AJ. Advances in adult asthma diagnosis and treatment and HEDQ in 2010. J Allergy Clin Immunol. 2011;127:116–22.PubMedCrossRefGoogle Scholar
  8. 8.
    •Rosenwasser LJ, Rothenberg ME. IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome. J Allergy Clin Immunol 2010; 125: 1245–6. This editorial by two well-known authors on the subject substantiates the potential role of anti–IL-5 in the treatment of respiratory conditions associated with eosinophilia. PubMedCrossRefGoogle Scholar
  9. 9.
    Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985–93. This article highlights the prednisone sparing effect of anti–IL-5 in patients with asthma and sputum eosinophilia.PubMedCrossRefGoogle Scholar
  10. 10.
    Horne NS, Narayan AR, Young RM, Frieri M. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmunity Reviews. 2006;5:160–4.PubMedCrossRefGoogle Scholar
  11. 11.
    ••Phillips EJ, Chung W-H, Mockenhaupt M et al., Drug hypersensitivity: Pharmacogenetics and clinical syndromes, J Allergy Clin Immunol 2011; 127: S60-6. This article is the latest in a series indicating the role of eosinophils in drug reactions. PubMedCrossRefGoogle Scholar
  12. 12.
    Kaufman LD, Krupp LB. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol. 1995;25(7):560–7.CrossRefGoogle Scholar
  13. 13.
    Nagai Y, Mori T, Abe T, Nomura G. Immediate-type allergy against human insulin associated with type with marked eosinophilia in type 2 diabetic patient. Endocr J. 2001;48:311–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Becker Y. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the TH1/TH2 cytokine balance toward increased levels of the cytokines and IgE, markers of allergy: a review. Virus Genes. 2006;33:235–52.PubMedGoogle Scholar
  15. 15.
    Wilson ME, Weller PF. Eosinophilia. In: Guerrant RL, Walker DH, Weller PF, editors. Tropical infectious diseases: principles, pathogens and practice. Philadelphia: Churchill Livingstone; 2006. p. 1478–95.Google Scholar
  16. 16.
    Saubolle MA, McKellar PP, Sussland D. Epidemiologic, clinical, and diagnostic aspects of coccidioidomycosis. J Clin Microbiol. 2007;45(1):26–30.PubMedCrossRefGoogle Scholar
  17. 17.
    Frieri M, Akkina S, Anand P. A case of persistent eosinophilia in lupus nephritis. Ann Allergy Asthma Immunol. 2011;107:P108.Google Scholar
  18. 18.
    Simon HU, Seger R. Hyper-IgE syndrome associated with an IL-4-producing γ/δ + T-cell clone. J Allergy Clin Immunol. 2007;119:246–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Schaffer JV. The changing face of graft-versus-host disease. Semin Cutan Med Surg. 2006;25:190–200.PubMedCrossRefGoogle Scholar
  20. 20.
    Jacobsohn DA, Schechter T, Seshadri R, et al. Eosinophilia correlates with the presence or development of chronic graft-versus-host disease in children. Transplantation. 2004;77:1096–100.PubMedCrossRefGoogle Scholar
  21. 21.
    Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol. 2004;77(1):82–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Frieri M. Mastocytosis, Chapter 14. Humana Press, 2009.Google Scholar
  23. 23.
    Shahzad G, Mustacchia P, Frieri M. Role of mucosal inflammation in eosinophilic esophagitis: Review of the literature, International Scholarly Research Network (ISRN) Gastroenterology, vol. 2011, Article ID 468073, 7pages, 2011.Google Scholar
  24. 24.
    ••Liacouras CA, Furuta GT, Hirano I, Atkins D et al., Eosinophilic esophagitis: Updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011; 128: 3–20. This article is a comprehensive review of the latest about the etiology, pathogenesis, and treatment of EE. PubMedCrossRefGoogle Scholar
  25. 25.
    Stein ML, Collins MH, Villanueva JM, et al. Anti-interleukin-5(mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol. 2007;118:1312–9.CrossRefGoogle Scholar
  26. 26.
    Blanchard N, Wang KF, Stringer, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest. 2006;116(2):536–47.PubMedCrossRefGoogle Scholar
  27. 27.
    Arora S, Yamazaki K. Eosinophilic esophagitis: asthma of the esophagus? Clin Gastroenterol Hepatol. 2004;2(7):523–30.PubMedCrossRefGoogle Scholar
  28. 28.
    Rothenberg ME. Biology and treatment of eosinophilic esophagitis. Gastroenterology. 2009;137(4):1238–49.PubMedCrossRefGoogle Scholar
  29. 29.
    Knight K, Blázquez AB, Zhang S, Mayer L, Sampson HA, Berin MC. CD4 T cells activated in the mesenteric lymph node mediate gastrointestinal food allergy in mice. Am J Physiol. 2007;293(6):G1234–43.Google Scholar
  30. 30.
    Rothenberg ME: Eosinophilic Gastroenteropathies. In Middleton’s Allergy Principles and Practice. Edited by Adkinson FN, Busse WW, Bochner BS et al. (eds), Elsevier; 2008: 879–891.Google Scholar
  31. 31.
    Foroughi S, Prussin C. Clinical management of eosinophilic gastrointestinal disorders. Curr Allergy Asthma Rep. 2005;5:259–61.PubMedCrossRefGoogle Scholar
  32. 32.
    Campos LE, Pereira LF. Pulmonary eosinophilia. J Bras Pneumol. 2009;35(6):561–73Google Scholar
  33. 33.
    Allen JN, Magro CM, King MA. The eosinophilic pneumonias. Semin Respir Crit Care Med. 2002; Apr;23(2):127–34.Google Scholar
  34. 34.
    Alam M, Burki NK. Chronic eosinophilic pneumonia: a review. South Med J. 2007 Jan;100(1):49–53Google Scholar
  35. 35.
    Ionescu MA, Rivet J, Daneshpouy M, et al. In situ eosinophil activation in 26 primary cutaneous T-cell lymphomas with blood eosinophilia. J Am Acad Dermatol. 2005;52:32–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Samoszuk M, Nansen L. Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin’s disease with eosinophilia. Blood. 1990;75:13–6.PubMedGoogle Scholar
  37. 37.
    Cordovi, MV, Verma, V, Gotlieb V Frieri M. Lymphocyte rich Hodgkin’s lymphoma presented with warm hemolytic anemia. a case report and literature review. Case Reports in Hematology, 2011.Google Scholar
  38. 38.
    Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndrome. Allergy. 2004;59:673–89.PubMedCrossRefGoogle Scholar
  39. 39.
    Gotlib J, Cross NCP, Gilliland DG. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Best Pract Res Clin Haematol. 2006;3:535–69.CrossRefGoogle Scholar
  40. 40.
    Bain BJ. Cytogenetic and molecular genetic aspects of eosinophilic leukemias. Br J Haematol. 2003;122:173–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Keung YK, Beaty M, Steward W, et al. Chronic myelocitic leukemia with eosinophilia, t(9,12)(q34;p13) and ETV6-ABL gene rearrangement: case report and review of the literature. Cancer Genet Cytogenet. 2002;138:139–42.PubMedCrossRefGoogle Scholar
  42. 42.
    Chang HW, Leong KH, Koh DR, et al. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood. 1999;93:1651–7.PubMedGoogle Scholar
  43. 43.
    Fletcher S, Bain B. Eosinophilic leukaemia. Br Med Bull. 2007;81–2:115–27.CrossRefGoogle Scholar
  44. 44.
    Weller PF: Eosinophilia and Eosinophil-Related Disorders. In: Middleton’s Allergy Principles and Practice. Edited by Adkinson FN, Busse WW, Bochner BS et al. Elsevier; 2008: 859–877.Google Scholar
  45. 45.
    Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes as a therapeutic target for imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201–14.PubMedCrossRefGoogle Scholar
  46. 46.
    Tefferi A. Modern diagnosis and treatment of primary eosinophilia. Acta Haematol. 2005;114(1):52–60.PubMedCrossRefGoogle Scholar
  47. 47.
    Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003;101(12):4714–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Jain N, Cortes J, Quintas-Cardama A, et al. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res. 2009;33(6):837–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Nand R, Bryke C, Kroft SH, et al. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosin kinase inhibitors. Leuk Res. 2009;33(8):1144–6.PubMedCrossRefGoogle Scholar
  50. 50.
    Newberry AM, Williams DN, Stauffer WM, et al. Strongyloides hyperinfection presenting as acute respiratory failure and gram-negative sepsis. Chest. 2005;128:3681–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Division of Allergy and Immunology, Department of Medicine and PediatricsAlbany Medical CollegeAlbanyUSA
  2. 2.Division of Allergy ImmunologyNassau University Medical CenterEast MeadowUSA

Personalised recommendations